Randy Daigle, MD
Family Medicine · Sunset, LANPI 1558361865
Payments from drug & device makers
Across 201 payments — averaging $13.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$401
- Kowa Pharmaceuticals America, Inc.$141
- AstraZeneca$120
- Novo Nordisk$97
- Novartis$76
- plus $764 from 22 others
What the payments were for
- Food & beverage$2,693100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 101 | $1,093 |
| Amgen | 27 | $401 |
| Kowa Pharmaceuticals America, Inc. | 9 | $141 |
| AstraZeneca | 8 | $120 |
| Novo Nordisk | 6 | $97 |
| Novartis | 5 | $76 |
| Sanofi-aventis U.S. LLC | 4 | $66 |
| Lilly USA, LLC | 4 | $65 |
| Pfizer | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| GSK | 3 | $51 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Abbott | 2 | $38 |
| Exact Sciences | 2 | $33 |
| Sunovion Pharmaceuticals Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Eisai Inc. | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Astellas Pharma US Inc | 2 | $23 |
| Alkermes, Inc. | 1 | $23 |
| Biogen | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $20 |
| Bayer | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
How this compares
$2,693 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 159 | $171,864 |
| EliquisApixaban | 185 | $119,009 |
| MounjaroTirzepatide | 46 | $71,196 |
| JanuviaSitagliptin Phosphate | 63 | $55,185 |
| JardianceEmpagliflozin | 81 | $49,562 |
| TrulicityDulaglutide | 24 | $38,161 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $37,948 |
| XareltoRivaroxaban | 52 | $34,596 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $34,194 |
| AristadaAripiprazole Lauroxil | 11 | $30,971 |
| LinzessLinaclotide | 39 | $28,669 |
| FarxigaDapagliflozin Propanediol | 41 | $23,024 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $21,542 |
| Victoza 3-PakLiraglutide | 12 | $20,630 |
| BelsomraSuvorexant | 42 | $18,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $97 | $171,864159 claims |
| PfizerEliquis, Premarin | $64 | $125,953216 claims |
| Lilly USA, LLCMounjaro, Trulicity | $65 | $109,35670 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $120 | $50,96888 claims |
| Boehringer IngelheimJardiance | $15 | $49,56281 claims |
| GSKTrelegy Ellipta | $51 | $37,94849 claims |
| AbbVieLinzess, Synthroid | $1,093 | $32,630107 claims |
| Alkermes, Inc.Aristada | $23 | $30,97111 claims |
| Astellas Pharma US IncVeozah | $23 | $6,64212 claims |
| Aimmune Therapeutics, Inc.Zenpep | $20 | $3,58712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Sunset
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.